Leading Innovation and Delivering 21st Century Medicines
January 16, 2019
Newly published research has identified how the immune system senses nanomedicines and triggers their elimination
In a newly published collaborative study in Nature Nanotechnology (https://www.nature.com/articles/s41565-018-0344-3), between Professor Moein Moghimi at Newcastle University, U.K., and a founding member of SMDG, a life sciences and biotechnology company, and researchers at the University of Colorado, the mechanism by which the human immune system recognizes and rejects nanoparticles has been deciphered to help researchers find more effective ways to deliver nanomedicines.
SMDG announces the addition of Geoff Lewis as its Senior Vice President, Legal Counsel. Lewis brings over a billion dollars of transactional experience in securities, IPOs, mergers & acquisitions, corporate finance, joint ventures and contracts with one of the largest corporate law firms in the world and three NYSE-listed companies.
Two World-renowned Neuroscientists Join SMDG's Distinguished Advisory Board
SM Discovery Group (SMDG), a life sciences and bio-nanotechnology company that has developed a ground-breaking nano-delivery system for unimpeded penetration of physiological barriers, announced the addition of Drs. Marc A. Dichter, M.D., Ph.D., and Dennis W. Choi, M.D., Ph.D. to its advisory board.
Geometry and particle hitch-hiking: A new window—and possible breakthrough—into improving nanopharmaceuticals for personalized medicine
Geometry and hitch-hiking are not the first things that come to mind regarding the immune system. However, the recent work by Moein Moghimi, Professor and Chair of pharmaceutics at Durham University, UK and collaborators shows that geometry is key in nanoparticle recognition by the immune system.